


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/723,003
	Filing Date	November 26, 2003
	First Named Inventor	Jing MA
	Art Unit	1642
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	16 + 67 Refs.	Attorney Docket Number 549062000200

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 (6 pages in duplicate) 2. References (67) 3. Return receipt postcard
<div style="border: 1px solid black; padding: 5px; min-height: 100px;"> Remarks </div>		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Jie Zhou, Reg. No. 52,395	(Customer No. 25226)
Signature		
Date	May 3, 2004	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 3, 2004

Signature: Martina Placid (Martina Placid)



PATENT
Docket No. 549062000200

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on May 3, 2004.

Martina Placid

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Jing MA et al.

Serial No.: 10/723,003

Filing Date: November 26, 2003

For: PREPARATION AND APPLICATION
OF ANTI-TUMOR BIFUNCTIONAL
FUSION PROTEINS

Examiner: Not Yet Assigned

Group Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are

not submitted. Copies of foreign documents and non-patent literature are submitted herewith. Applicants bring to the attention of the Examiner co-pending related applications (documents 1 and 2 on the attached form PTO-1449) which copies are not being submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 549062000200. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 3, 2004

Respectfully submitted,

By: 
Jie Zhou
Registration No. 52,395

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5922
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/26/2001	09/915,746	Ma et al.			
	2.	11/26/2003	10/722,849	Ma			
	3.	06/19/2003	200030113341	Lynch et al.			
	4.	08/07/2003	20030148516	Lyman et al.			
	5.	09/04/2003	2003/0165531	Lynch et al.			
	6.	10/02/2003	2003/0186214	Yan et al.			
	7.	10/23/1990	4,965,195	Namen et al.			
	8.	11/06/1990	4,968,607	Dower et al.			
	9.	09/27/1994	5,350,683	Sims et al.			
	10.	08/13/1996	5,545,806	Lonberg et al.			
	11.	10/29/1996	5,569,825	Lonberg et al.			
	12.	04/29/1997	5,624,821	Winter et al.			
	13.	04/29/1997	5,625,126	Lonberg et al.			
	14.	05/27/1997	5,633,425	Lonberg et al.			
	15.	08/26/1997	5,661,016	Lonberg et al.			
	16.	10/14/1997	5,677,171	Hudziak et al.			
	17.	01/06/1998	5,705,157	Greene			
	18.	01/20/1998	5,710,248	Grose			
	19.	12/01/1998	5,843,423	Lyman et al.			
	20.	02/20/2001	6,190,655	Lyman et al.			
	21.	02/27/2001	6,194,551	Idusogie et al.			
	22.	09/18/2001	6,291,661	Graddis et al.			
	23.	01/01/2002	6,335,429	Cai et al.			
	24.	01/29/2002	6,342,611	Weber et al.			
	25.	05/21/2002	6,391,575	Fritz et al.			
	26.	06/04/2002	6,399,061	Anderson et al.			
	27.	09/24/2002	6,455,043	Grillo-Lopez			

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

	28.	10/01/2002	6,458,356	Arakawa et al.			
	29.	02/18/2003	6,521,740	Sims et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	30.	05/09/1990	EP 0 367 566	Europe				
	31.	12/11/1991	EP 0 460 846	Europe				
	32.	11/18/1999	WO 99/58572	WIPO				
	33.	06/06/2002	WO 02/43478	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	34.	Angal, S. et al. (1993). "A Single Amino Acid Substitution Abolishes The Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <i>Mol. Immunol.</i> 30(1):105-108.
	35.	Banchereau, J. et al. (1998). "Dendritic Cells and the Control of Immunity," <i>Nature</i> 392:245-252.
	36.	Banchereau, J. et al. (2000). "Immunobiology of Dendritic Cells," <i>Ann Rev. Immunol.</i> 18:767-811.
	37.	Bastin, P. et al. (1996). "A Novel Epitope Tag System to Study Protein Targeting and Organelle Biogenesis in <i>Trypanosoma Brucei</i> ," <i>Mol. & Biochem. Parasitology</i> 77:235-239.
	38.	Brodowicz, T. et al. (2001). "Anti-Her-2/neu Antibody Induces Apoptosis in Her-2/neu Overexpressing Breast Cancer Cells Independently From p53 Status," <i>Br. J. Cancer</i> 85(11):1764-1770.
	39.	Budihardjo, I et al. (1999). "Biochemical Pathways of Caspase Activation During Apoptosis," <i>Ann. Rev. Cell Dev. Biol.</i> 15:269-290.
	40.	Burstein, H. et al. (2003). "Trastuzumab and Vinorelbine as First-Line Therapy for Her2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm," <i>J. Clin. Oncol.</i> 21(15):2889-2895.
	41.	Carter, P. et al. (1992). "Humanization of an Anti-p185 ^{Her2} Antibody for Human Cancer Therapy," <i>PNAS USA</i> 89:4285-4289.
	42.	Chen, C-F. et al. (1998). "Expression Vector Containing an N-Terminal Epitope Tag for <i>Dictyostelium Discoideum</i> ," <i>BioTechniques</i> 25(1):22 and 24.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 549062000200

Application Number 10/723,003

Applicant

Jing MA et al.

Filing Date November 26, 2003

Group Art Unit 1642

Mailing Date May 3, 2004

43.	Choudhury, A. et al. (1997). "Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia," <i>Blood</i> 89(4):1133-1142.
44.	Cole, S.P.C. et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> pp. 77-96.
45.	Coloma, M. J. et al. (1992). "Novel Vectors for the Expression of Antibody Molecules Using Variable Regions Generated by Polymerase Chain Reaction," <i>J. Immunol. Methods</i> 152:89-104.
46.	Coloma, M. J. et al. (1997). "Design and Production of Novel Tetravalent Bispecific Antibodies," <i>Nat. Biotech</i> 15:159-163.
47.	Cosman, D. et al. (1984). "Cloning, Sequence and Expression of Human Interleukin-2 Receptor," <i>Nature</i> 312:768-771.
48.	Cosman, D. et al. (1986). "High Level Stable Expression of Human Interleukin-2 Receptors in Mouse Cells Generates Only Low Affinity Interleukin-2 Binding Sites," <i>Mol. Immunol.</i> 23(9):935-941.
49.	Coulie, P. et al. (1992). "Precursor Frequency Analysis of Human Cytolytic T Lymphocytes Directed Against Autologous Melanoma Cells," <i>Int. J. Cancer</i> 50:289-297.
50.	Crombet-Ramos, T. et al. (2002). "Antiproliferative, Antiangiogenic and Proapoptotic Activity of H-R3: A Humanized Anti-EGFR Antibody," <i>Int. J. Cancer</i> 101:567-575.
51.	Di Nicola, M. et al. (1998). "Human Dendritic Cells: Natural Adjuvants in Antitumor Immunotherapy," <i>Cytokines Cell Mol. Therapy</i> 4:265-273.
52.	Fiers, W. et al. (1978). "Complete Nucleotide Sequence of SV40 DNA," <i>Nature</i> 273:113-120.
53.	Fong, C. L. et al. (2000). "Dendritic Cells in Cancer Immunotherapy," <i>Ann. Rev. Immunol.</i> 18:245-273.
54.	Fong, C.L. et al. (2001). "Altered Peptide Ligand Vaccination With Flt3 Ligand Expanded Dendritic Cells For Tumor Immunotherapy," <i>Proc. Natl. Acad. Sci USA</i> 98(15):8809-8814.
55.	Fong, C.L. et al. (2002). "Generation of Potent and Specific Cellular Immune Responses Via In Vivo Stimulation of Dendritic Cells by pNGVL3-hFLex Plasmid DNA and Immunogenic Peptides," <i>Gene Therapy</i> 9:1127-1138.
56.	Galfr�, G. et al. (1981). "Preparation of Monoclonal Antibodies: Strategies and Procedures," <i>Methods In Enzymol.</i> 73:3-46.
57.	Genbank Accession No. X06659 (or 001459) last updated February 10, 1999, located at < http://www.ncbi.nlm.gov/entrez/viewer.fcgi?db=nucleotide&val > on February 17, 2004, 2 pages.
58.	Genbank Accession No.U03858. last updated July 19, 1994, located at < http://www.ncbi.nlm.gov/entrez/viewer.fcgi?db=nucleotide&val > on February 17, 2004, 2 pages.
59.	Genbank Accession No. U04806. last updated May 11, 1994, located at < http://www.ebi.ac.uk/cgi-bin/emblfetch?style=html > on February 17, 2004, 2 pages.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

60.	Genbank Accession No.U29874. last updated February 29, 1996, located at < http://www.ncbi.nlm.gov/entrez/viewer.fcgi?db=nucleotide&val > on February 17, 2004, 3 pages.
61.	Gilliland, D. G. et al. (2002). "Role of FLT3 in Leukemia," <i>Curr. Opin. Hematol.</i> 9:274-281.
62.	Gluzman, Y. (1981). "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants," <i>Cell</i> 23:175-182.
63.	Green, L. et al. (1998). "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes," <i>J. Exp. Med.</i> 188:483-495.
64.	Grütter, M. G. (2000). "Caspases: Key Players in Programmed Cell Death," <i>Curr. Opin. Structural Biol.</i> 10:649:655.
65.	Hannum, C. et al. (1994). "Ligand for FLT3/FLK2 Receptor Tyrosine Kinase Regulates Growth of Haematopoietic Stem Cells and Is Encoded by Variant RNAs," <i>Nature</i> 368:643-648.
66.	Harbury, P. B. et al. (1993). "A Switch Between two-, Three-, and Four-Stranded Coiled Coils in GCN4 Leucine Zipper Mutants," <i>Science</i> 262:1401-1407.
67.	Hatakeyama, M. et al. (1989). "A Restricted Cytoplasmic Region of IL-2 Receptor β Chain Is Essential for Growth Signal Transduction but Not For Ligand Binding and Internalization," <i>Cell</i> 59:837-845.
68.	Herbst, R.S. et al. (2001). "IMC-C225, an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, For Treatment of Head and Neck Cancer," <i>Expert Opin. Biol. Ther.</i> 1(4):719-732.
69.	Jakobovits, A.(1998). "Production and Selection of Antigen-Specific Fully Human Monoclonal Antibodies from Mice Engineered with Human Ig Loci," <i>Adv. Drug Del. Rev.</i> 31:33-42.
70.	Karlsson, R. et al. (1991). "Kinetic Analysis of Monoclonal Antibody-Antigen Interactions with a New Biosensor Based Analytical System," <i>J. Immunol. Methods</i> 145:229-240.
71.	Kawakami, Y. et al. (1989). "IL-4 Regulates IL-2 Induction of Lymphokine-Activated Killer Activity From Human Lymphocytes," <i>The J. of Immunol.</i> 142(10):3452-3461.
72.	Kozbor, D. et al. (1983). "The Production of Monoclonal Antibodies From Human Lymphocytes," <i>Immunol. Today</i> 4(3):72-79.
73.	Luckow, V. A. et al. (1988). "Trends in the Development of Baculovirus Expression Vectors," <i>BioTechnology</i> 6:47-55.
74.	Lyman, S. D. et al. (1993). "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," <i>Cell</i> 75:1157-1167.
75.	Marks, J. D. et al. (1991). "By-Passing Immunization Human Antibodies from V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597.
76.	McMahan, C. et al. (1991). "A Novel IL-1 Receptor, Cloned from B Cells By Mammalian Expression, Is Expressed in Many Cell Types," <i>EMBO J.</i> 10:2821-2832.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

77.	Nagelkerken, B. et al. (1997). "A Novel Epitope Tag for the Detection of rabGTPases," <i>Electrophoresis</i> 18:2694-2698.
78.	Okayama, H. et al. (1983). "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," <i>Mol. Cell. Biol.</i> 3:280-289.
79.	Oláh, Z. et al. (1994). "A Cloning and e-Epitope-Tagging Insert for the Expression of Polymerase Chain Reaction-Generated cDNA Fragments in <i>Escherichia Coli</i> and Mammalian Cells," <i>Analytical Biochem</i> 221:94-102.
80.	Pèron, J-M. et al. (1998). "FLT3-Ligand Administration Inhibits Liver Metastases: Role of NK Cells," <i>The J. of Immunol.</i> 161:6164-6170.
81.	Pitti, R. M. et al. (1996). "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>J. Biol. Chem.</i> 271(22):12687-12690.
82.	Prickett, K. S. et al. (1989). "A Calcium-Dependent Antibody for Identification and Purification of Recombinant Proteins," <i>BioTechniques</i> 7(6):580-584.
83.	Prodromou, C. et al. (1992). "Protocol Recursive PCR: A Novel Technique for Total Gene Synthesis," <i>Protein Eng.</i> 5(8):827-829.
84.	Rosnet, O. et al. (1993). "Human FLT3/FLK2 Gene: cDNA Cloning and Expression in Hematopoietic Cells," <i>Blood</i> 82(4):1110-1119.
85.	Rosnet, O. et al. (1996). "Human FLT3/FLK2 Receptor Tyrosine Kinase is Expressed at the Surface of Normal and Malignant Hematopoietic Cells," <i>Leukemia</i> 10:238-248.
86.	Rüdiger, M. et al. (1997). "Epitope Tag-Antibody Combination Useful for the Detection of Protein Expression in a Prokaryotic and Eukaryotic Cells," <i>BioTechniques</i> 23(1):96-97.
87.	Shimizu, M. et al. (1996). "A Trial to Kill Tumor Cells Through Fas (CD95)-Mediated Apoptosis <i>In Vivo</i> ," <i>Biochem. Biophys. Res. Commun.</i> 228(2):375-379.
88.	Small, D. et al. (1994). "STK-1, the Human Homolog of Flk-2/Flt-3, is Selectively Expressed in CD34+ Human Bone Marrow Cells and is Involved in the Proliferation of Early Progenitor /Stem Cells," <i>PNAS USA</i> 91:459-463.
89.	Spiridon, C. I. (2002). "Targeting Multiple Her-2 Epitopes With Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line <i>In Vitro</i> and <i>In Vivo</i> ," <i>Clinical Cancer Res.</i> 8:1720-1730.
90.	Tolbert, L. M. et al. (1998). "Antibody to Epitope Tag Induces Internalization of Human Muscarinic Subtype 1 Receptor," <i>J. Neurochem.</i> 70(1):113-119.
91.	Tseng, C-P. et al. (1996). "Functional Expression and Characterization of the Mouse Epitope Tag-Protein Kinase C Isoforms, α , β I, β II, γ , δ and ϵ ," <i>Gene</i> 169:287-288.
92.	Urdal, D. L. et al. (1984). "Lymphokine Purification by Reversed-Phase High-Performance Liquid Chromatography," <i>J. of Chromatog.</i> 296:171-179.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 549062000200	Application Number 10/723,003
	Applicant Jing MA et al.	
	Filing Date November 26, 2003	Group Art Unit 1642
	Mailing Date May 3, 2004	

93.	Wang, L-F. et al. (1996). "BTag: A Novel Six-Residue Epitope Tag for Surveillance and Purification of Recombinant Proteins," <i>Gene</i> 169(1):53-58.
94.	Watson, J. D. eds. et al. (1987). "The Fine Structure of Bacterial and Phage and Genes," <i>In Molecular Biology of The Gene</i> , 4th Edition, The Benjamin /Cummings Pub. Co. Inc. pp. 224-225.
95.	Xie, L. Y et al. (1998). "Epitope Tag Mapping of the Extracellular and Cytoplasmic Domains of the Rat Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor," <i>Endocrinology</i> 139(11):4563-4567.
96.	Zitvogel, L. et al. (1996). "Therapy of Murine Tumors with Tumor Peptide-Pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-Associated Cytokines," <i>J. Exp. Med.</i> 183:87-97.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.